Abstract
The successful use of theranostic twins in neuroendocrine tumors (NET) is the pioneering approach to radionuclide therapy in other tumor types. 64Cu/18F PSMA for molecular imaging with PET-CT and peptide radioligand therapy (PRLT) with 177Lu labeled PSMA inhibitors are the next theranostic twins in nuclear medicine. 68Ga/ 64Cu/18F PSMA PET-CT detects metastatic prostate cancer with high diagnostic sensitivity and specificity and can be used to select patients for PRLT and evaluate therapy response. Radionuclide therapy with 177Lu-PSMA inhibitors has been shown to be effective in the treatment of metastatic CRPC.
Keywords: Peptide radioligand therapy, 64CuCl2, CRPC, PET-CT, NET, prostate cancer, glioblastoma, melanoma.
Current Radiopharmaceuticals
Title:Theranostics of Metastatic Prostate Cancer Applying 64Cu/18F/68Ga PSMA PET-CT and 177Lu Radiopharmaceuticals
Volume: 14 Issue: 4
Author(s): Siroos Mirzaei*, Fairoz Mohammed and Shahin Zandieh
Affiliation:
- Department of Nuclear Medicine with PET-Center, Wilhelminenspital, Vienna,Austria
Keywords: Peptide radioligand therapy, 64CuCl2, CRPC, PET-CT, NET, prostate cancer, glioblastoma, melanoma.
Abstract: The successful use of theranostic twins in neuroendocrine tumors (NET) is the pioneering approach to radionuclide therapy in other tumor types. 64Cu/18F PSMA for molecular imaging with PET-CT and peptide radioligand therapy (PRLT) with 177Lu labeled PSMA inhibitors are the next theranostic twins in nuclear medicine. 68Ga/ 64Cu/18F PSMA PET-CT detects metastatic prostate cancer with high diagnostic sensitivity and specificity and can be used to select patients for PRLT and evaluate therapy response. Radionuclide therapy with 177Lu-PSMA inhibitors has been shown to be effective in the treatment of metastatic CRPC.
Export Options
About this article
Cite this article as:
Mirzaei Siroos *, Mohammed Fairoz and Zandieh Shahin, Theranostics of Metastatic Prostate Cancer Applying 64Cu/18F/68Ga PSMA PET-CT and 177Lu Radiopharmaceuticals, Current Radiopharmaceuticals 2021; 14 (4) . https://dx.doi.org/10.2174/1874471013666200908122845
DOI https://dx.doi.org/10.2174/1874471013666200908122845 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Abnormal Functional and Structural Asymmetry as Biomarker for Schizophrenia
Current Topics in Medicinal Chemistry Tumour Mutation Profiling with High-throughput Multiplexed Genotyping: A Review of its Use for Guiding Targeted Cancer Therapy
Current Cancer Therapy Reviews Regulation of Cell Migration and Invasion by Specific Modules of uPA: Mechanistic Insights and Specific Inhibitors
Current Drug Targets Multifunctional Hydroxyapatite-based Nanoparticles for Biomedicine: Recent Progress in Drug Delivery and Local Controlled Release
Current Mechanics and Advanced Materials Role of Oxygen in Cancer: Looking Beyond Hypoxia
Anti-Cancer Agents in Medicinal Chemistry Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets Hepatoma-Derived Growth Factor in Carcinogenesis and Cancer Progression
Current Drug Therapy Pharmacometrics in Dose Finding or Dose Optimization of Anti-Retroviral and Anti-Tubercular Drugs
Infectious Disorders - Drug Targets Interleukin-18: Biology and Role in the Immunotherapy of Cancer
Current Medicinal Chemistry Molecular Signatures of Biomarkers in Cancer Development, Diagn osis, and its Prognostic Accuracy
Current Biomarkers (Discontinued) Survivin: Role in Normal Cells and in Pathological Conditions
Current Cancer Drug Targets The Immunosuppressive Role of Adenosine A2A Receptors in Ischemia Reperfusion Injury and Islet Transplantation
Current Diabetes Reviews Nanoparticles: Properties and Applications in Cancer Immunotherapy
Current Pharmaceutical Design Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Current Pharmaceutical Design Imidazoquinolines: Recent Developments in Anticancer Activity
Mini-Reviews in Medicinal Chemistry Potential Crossreactivity of Human Immune Responses Against HCMV Glycoprotein B
Current Drug Discovery Technologies Recent Advances in Peptide-Based Approaches for Cancer Treatment
Current Medicinal Chemistry Realizing the Potential of Health-Promoting Rosehips from Dogroses (Rosa sect. Caninae)
Current Bioactive Compounds Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design